Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Imunon (IMNN – Research Report). The associated price target was raised to $14.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on Imunon’s strategic advancements in their clinical trials and promising results from their ongoing research. The company is preparing to initiate a Phase 3 trial for IMNN-001 in combination with neoadjuvant chemotherapy for advanced ovarian cancer, which is set to enroll approximately 500 women. This trial builds on the success of the OVATION 2 trial, which showed a significant improvement in overall survival rates, and indicates strong interest from physicians familiar with the treatment.
Additionally, Imunon’s development of the IMNN-101 DNA plasmid vaccine for COVID-19 has shown positive initial results in terms of safety and immune response. The vaccine, designed using the company’s proprietary technology, demonstrated a sustained increase in neutralizing antibody titers and cross-reactivity against newer variants, suggesting broader protective potential. These factors collectively contribute to Bodnar’s Buy rating, reflecting confidence in Imunon’s innovative approaches and potential market impact.